GBA1 and Parkinson disease: Our PCA-based classification provides a scalable and biologically informed tool for prognostic assessment and future stratification of PD patients with heterozygous GBA1 variants, particularly in the context of clinical trials evaluating targeted therapies, such as chaperone molecules aimed at stabilizing GCase.